Search Medical Condition
Please enter condition
Please choose location from dropdown

Bethage, New York Clinical Trials

A listing of Bethage, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (347) clinical trials

Observational Registry of H.P. Acthar Gel for Multiple Sclerosis Relapse

H.P. Acthar Gel (repository corticotropin injection) contains a porcine analogue of adrenocorticotropic hormone (ACTH) for intramuscular or subcutaneous use. H.P. Acthar Gel (Acthar Gel) was initially approved by the FDA in 1952 and has multiple indications of use. This registry will evaluate the use of Acthar Gel for the treatment ...

Phase N/A

0.35 miles

Learn More »

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine

The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.

Phase

2.34 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

This study is an international phase 3 randomized, open-label, parallel group efficacy and safety study to evaluate oral daily relugolix 120 mg in patients with androgen-sensitive advanced prostate cancer who require at least 1 year (48 weeks) of continuous androgen deprivation therapy. Relugolix 120 mg orally once daily or leuprolide ...

Phase

2.34 miles

Learn More »

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks.

Phase

2.34 miles

Learn More »

A Study to Evaluate the Efficacy Safety and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

At Screening (Visit 1), subjects will enter into a 4-week open label tamsulosin hydrochloride 0.4 mg QD run-in period prior to being randomized into the 12-week double-blind treatment period (Visit 2). At conclusion of the 4-week tamsulosin hydrochloride run-in period, subjects will complete a 3-day diary just prior to Baseline ...

Phase

2.34 miles

Learn More »

Randomized Controlled Trial of ProstAtak Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

The purpose of this study is to evaluate the effectiveness of ProstAtak immunotherapy in patients undergoing active surveillance for localized prostate cancer. ProstAtak involves the use of aglatimagene besadenovec (AdV-tk) to kill tumor cells and stimulate a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the ...

Phase

2.34 miles

Learn More »

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

This is a multi-site, placebo-controlled, double-blind, randomized withdrawal, time to intervention study with a duration of up to 36 weeks, consisting of 5 periods: Screening Period: up to 4 weeks duration; Open-Label Titration Period (Titration Period): up to 4 weeks duration; Open-Label Treatment Period (Open-Label Period): 12 weeks duration; Double-Blind ...

Phase

2.34 miles

Learn More »

Dimethyl Fumarate (DMF) Observational Study

Patients aged 12 to under 18 may be included where enrollment of pediatric patients in this study is considered observational and is permissible by local regulations.

Phase N/A

2.34 miles

Learn More »

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

A Phase 2a, randomized, double-blind, placebo-controlled, 3-arm parallel group study to evaluate the efficacy and safety of AMG 301 in subjects with chronic migraine or episodic migraine.

Phase

2.34 miles

Learn More »

Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

The purpose of this study is to evaluate the effectiveness of ProstAtak immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to ...

Phase

2.34 miles

Learn More »